The purpose of this study is to analyze the differences of blood sugar level and glycemic variability between sulfonylurea and DPP-4 inhibitor groups applying CGMS for a chosen number of type 2 DM patients. The investigators also reveal influences of each drugs on cardiovascular risk factors by measuring related biomarkers.
We enroll patients with type 2 DM with uncontrolled glucose level on Metformin monotherapy over 1000mg /day (HbA1C over 7%). Before drug administration, we conduct basal lab study including CGMS. After 3 month of random administration of vildagliptin or glimepiride, we check CGMS, glucose levels, CV biomarkers, and estimate hypoglycemic index. We replace with the other drug for 3 months, and then conduct the same measurements. No wash-out period is necessary since result variables are measured after the 3 months of administration for a different drug.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
Seoul National University Hospital
Seoul, South Korea
Glycemic variability index
Time frame: before and after 3 months of each drug administration
Cardiovascular disease risk factor
Time frame: before and after 3 months of each drug administration
glucose profile and lipid profile
Time frame: before and after 3 months of each drug administration
hypoglycemic index
Time frame: before and after 3 months of each drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.